CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C on January 7, 2002

Blay 1. Kunny Barry C. Kjonjey

OIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David H. MCDANIEL

Serial No.: 09/

09/876,157

Filing Date:

June 8, 2001

For:

ULTRASOUND ENHANCEMENT OF

PERCUTANEOUS DRUG ABSORPTION

Examiner:

Not yet assigned

Group Art Unit:

3763

PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend this application as follows:

In the Specification:

Please replace the paragraph beginning line 16 of page 5 with the following rewritten paragraph:

Figure 5A illustrates an example of a pretreatment of the stratum corneum.

Please replace the paragraph beginning line 18 of page 5 with the following rewritten paragraph:

Figure 5B illustrates an example of a coupling agent being applied and an ultrasound treatment being performed.

Serial No. 09/876,157 Docket No. 509582000110

Please replace the paragraph beginning line 20 of page 5 with the following rewritten paragraph:

Figure 5C illustrates an example of a coupling agent being removed and an active toical agent being applied.

Please replace the paragraph beginning line 22 of page 5 with the following rewritten paragraph:

Figure 5D illustrates an example of an active topical agent being removed after an appropriate time.

Please replace the paragraph beginning line 24 of page 5 with the following rewritten paragraph:

Figure 5E illustrates an example of a protective topical agent being applied.

Please replace the paragraph beginning line 26 of page 5 with the following rewritten

paragraph:

Figure 6 illustrates an example of an active topical agent which also serves as a coupling agent being applied, and an ultrasound treatment being performed.

Please replace the paragraph beginning line 1 of page 6 with the following rewritten paragraph:

Figure 7 illustrates an example of an injection of a drug or agent or autologous or donor fibroblast rich preparation.

Please replace the paragraph beginning line 3 of page 6 with the following rewritten paragraph:

Figures 8A, 8B, 8C and 8D illustrate examples of an embodiment using low energy laser therapy to stimlate (directly or indirectly) the production, proliferation, activation, or inhibition of the activity, structure or function of various biochemical or

1956157 THOFOE PATENT

Docket No. 509582000110

photochemical or biological processes (this example features stimulation of a human fibroblast).

Please replace the paragraph beginning line 12 of page 10 with the following rewritten paragraph:

The embodiment illustrated in Figure 4 is primarily as a 'biostimulating' process and not a destructive or ablative process, such as commonly used in today's art. Using laser therapy or ultrasound (or both) to produce heat at a subnecrotic damage or injury threshold is another possible embodiment. (An example might be trying to achieve a dermal temperature that affects collagen - perhaps beginning around 55-60°C.

Please replace the paragraph beginning line 18 of page 10 with the following rewritten paragraph:

Figure 4 illustrates an example of an embodiment using low energy laser therapy to stimulate (directly or indirectly) the production, proliferation, activation, or inhibition of the activity, structure or function of various biochemical or photochemical or biological processes so as to result (directly or indirectly) in effects that are beneficial to the structure, function or appearance of the skin and/or subcutaneous tissues or which results in the "rejuvenation" of photoaged, environmentally damaged or disease or drug/therapy altered skin or subcutaneous tissue.

REMARKS

The above amendments to the specification have been made to place the application in proper U.S. format and to conform with proper grammatical and idiomatic English. None of the amendments herein are made for reasons related to patentability. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made".

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 509582000110.

Respectfully submitted,

Dated:

January 7, 2002

 \mathbf{D}_{τ}

Wayne C. Jaesahke, Jr. Registration No. 38,503

Morrison & Foerster LLP

2000 Pennsylvania Avenue, N.W.

Washington, D.C. 20006-1888

Telephone: (202) 778-1446 Facsimile: (202) 263-8396

O986157 ... G1O70E
PATENT
Docket No. 509582000110

VERSION WITH MARKINGS TO SHOW CHANGES MADE

For the convenience of the Examiner, the changes made are shown below with deleted text in strikethrough and added text in underline.

In the Specification:

Please replace the paragraph beginning line 16 of page 5 with the following rewritten paragraph:

Figure 1.1 5A illustrates an example of a pretreatment of the stratum corneum.

Please replace the paragraph beginning line 18 of page 5 with the following rewritten paragraph:

Figure I.2 5B illustrates an example of a coupling agent being applied and an ultrasound treatment being performed.

Please replace the paragraph beginning line 20 of page 5 with the following rewritten paragraph:

Figure 1.3 5C illustrates an example of a coupling agent being removed and an active toical agent being applied.

Please replace the paragraph beginning line 22 of page 5 with the following rewritten paragraph:

Figure I.4 <u>5D</u> illustrates an example of an active topical agent being removed after an appropriate time.

Please replace the paragraph beginning line 24 of page 5 with the following rewritten paragraph:

Figure 1.4 5E illustrates an example of a protective topical agent being applied.

Please replace the paragraph beginning line 26 of page 5 with the following rewritten

paragraph:

Docket No. 509582000110

Figure II.2 6 illustrates an example of an active topical agent which also serves as a coupling agent being applied, and an ultrasound treatment being performed.

Please replace the paragraph beginning line 1 of page 6 with the following rewritten paragraph:

Figure III. 1 7 illustrates an example of an injection of a drug or agent or autologous or donor fibroblast rich preparation.

Please replace the paragraph beginning line 3 of page 6 with the following rewritten paragraph:

Figure III.1 illustrates an example Figures 8A, 8B, 8C and 8D illustrate examples of an embodiment using low energy laser therapy to stimlate (directly or indirectly) the production, proliferation, activation, or inhibition of the activity, structure or function of various biochemical or photochemical or biological processes (this example features stimulation of a human fibroblast).

Please replace the paragraph beginning line 12 of page 10 with the following rewritten paragraph:

The embodiment illustrated in Figure IV 4 is primarily as a 'biostimulating' process and not a destructive or ablative process, such as commonly used in today's art. Using laser therapy or ultrasound (or both) to produce heat at a subnecrotic damage or injury threshold is another possible embodiment. (An example might be trying to achieve a dermal temperature that affects collagen - perhaps beginning around 55-60°C.

Please replace the paragraph beginning line 18 of page 10 with the following rewritten paragraph:

Figure IV 4 illustrates an example of an embodiment using low energy laser therapy to stimulate (directly or indirectly) the production, proliferation, activation, or inhibition of the activity, structure or function of various biochemical or photochemical or biological processes so as to result (directly or indirectly) in effects that are beneficial to the structure, function or appearance of the skin and/or subcutaneous tissues or which results in the "rejuvenation" of photoaged, environmentally damaged or disease or drug/therapy altered skin or subcutaneous tissue.